Abstract:Influenza virus infection is an ongoing health and economic burden causing epidemics with pandemic potential, affecting 5–30% of the global population annually, and is responsible for millions of hospitalizations and thousands of deaths each year. Annual influenza vaccination is the primary prophylactic countermeasure aimed at limiting influenza burden. However, the effectiveness of current influenza vaccines are limited because they only confer protective immunity when there is antigenic similarity between the selected vaccine strains and circulating influenza isolates. The major targets of the antibody response against influenza virus are the surface glycoprotein antigens hemagglutinin (HA) and neuraminidase (NA). Hypervariability of the amino acid sequences encoding HA and NA is largely responsible for epidemic and pandemic influenza outbreaks, and are the consequence of antigenic drift or shift, respectively. For this reason, if an antigenic mismatch exists between the current vaccine and circulating influenza isolates, vaccinated people may not be afforded complete protection. There is currently an unmet need to develop an effective “broadly-reactive” or “universal” influenza vaccine capable of conferring protection against both seasonal and newly emerging pre-pandemic strains. A number of novel influenza vaccine approaches are currently under evaluation. One approach is the elicitation of an immune response against the “Achille’s heel” of the virus, i.e. conserved viral proteins or protein regions shared amongst seasonal and pre-pandemic strains. Alternatively, other approaches aim toward eliciting a broader immune response capable of conferring protection against the diversity of currently circulating seasonal influenza strains.In this review, the most promising under-development universal vaccine approaches are discussed with an emphasis on those targeting the HA glycoprotein. In particular, their strengths and potential short-comings are discussed. Ultimately, the upcoming clinical evaluation of these universal vaccine approaches will be fundamental to determine their effectiveness against preventing influenza virus infection and/or reducing transmission and disease severity.

Progress and perspectives of universal influenza vaccine

Progress towards the Development of a Universal Influenza Vaccine

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Research Progress in Broad Neutralizing Antibodies and Universal Vaccines Against Influenza A Virus

Flu Universal Vaccines: New Tricks on an Old Virus

The race toward a universal influenza vaccine: Front runners and the future directions

[Research and development technology platform and research progress of universal influenza vaccine]

Towards a universal influenza vaccine: different approaches for one goal

Progress on adenovirus-vectored universal influenza vaccines

Research and Development of Universal Influenza Vaccines.

Advances in Nucleic Acid Universal Influenza Vaccines

Influenza and Universal Vaccine Research in China

Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine

Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

How far have we reached in development of effective influenza vaccine?

Development of universal influenza vaccines based on influenza virus M and NP genes

Recent advances in “universal” influenza virus antibodies: the rise of a hidden trimeric interface in hemagglutinin globular head

Vaccine approaches conferring cross-protection against influenza viruses

M2e-Based Universal Influenza A Vaccines

Influenza vaccine: progress in a vaccine that elicits a broad immune response

Broad neutralizing antibody-based strategies to tackle influenza